Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hangzhou Xingsai Ruizhen Biotechnology

Request full access

Cell therapy and regenerative medicine development platform

ChinaFounded 2022Biotech & Life Sciences

About Hangzhou Xingsai Ruizhen Biotechnology

Hangzhou Xingsai Ruizhen Biotechnology Co., Ltd. (Celregen) is a platform-based company specializing in cell therapy and regenerative medicine. Founded in July 2022, the company was incubated by the New Drug Innovation Fund of Fosun Health Capital. Celregen has its headquarters in Hangzhou and a research and development center in Shanghai.

The company employs a business model that combines in-licensing of external technologies with its own in-house research and development. A key partnership was established in September 2022 with the Japanese startup Cellusion Inc., granting Celregen exclusive rights to develop, manufacture, and commercialize CLS001 in Greater China (mainland China, Hong Kong, Macau, and Taiwan). CLS001 is an iPSC-derived corneal endothelial cell substitute designed to treat bullous keratopathy, addressing the significant shortage of donor corneas. The agreement has a potential value exceeding $100 million, inclusive of upfront payments, milestones, and royalties.

Celregen's technology platform is centered on induced pluripotent stem cells (iPSCs). It encompasses rapid iPSC reprogramming, a proprietary CRISPR/Cas12b-based gene-editing system, and bioinformatics-guided differentiation techniques. This integrated platform supports the entire R&D process for iPSC-derived products. Beyond its lead program in corneal regeneration (CRG-101/CLS001), the company is also developing therapies for insulin-dependent diabetes (CRG-002) and exploring applications in tumor therapy through stem cell-derived CAR-NK treatments. The company's focus is on creating off-the-shelf allogeneic cell therapies for conditions with high unmet clinical needs.

In August 2022, Celregen secured 45 million yuan (approximately $6.67 million) in a seed funding round from Fosun Health Capital's New Drug Innovation Fund.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
21.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Diabetes, Ophthalmology, Crispr, Cell Therapy, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Mar 2025 $14M $55M Fosun Health Capital · SCI Advanced Technology Fund ↗
SEED✓Equity / VC Sep 2024 $2.8M $11M SCI Advanced Technology Fund · Fosun Health Capital ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Hangzhou Xingsai Ruizhen Biotechnology website traffic

Latest recorded traffic for Hangzhou Xingsai Ruizhen Biotechnology is 1K monthly website visits, up 88.7% over the last three months.

Latest monthly visits1K 3-month web change+88.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hangzhou Xingsai Ruizhen Biotechnology in its local ecosystem

Live from Dealroom

The Hangzhou Xingsai Ruizhen Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • SCI Advanced Technology Fund
  • Fosun Health Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hangzhou Xingsai Ruizhen Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hangzhou Xingsai Ruizhen Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.